Reinnervate and Tecan Sign Co-marketing Agreement
News Nov 27, 2012
Reinnervate Ltd and Tecan Trading AG, have signed a co-marketing agreement to develop a range of automated solutions for 3D cell culture, based on the Freedom EVO® liquid handling workstations and Reinnervate’s Alvetex®Scaffold 3D cell culturing technology.
Alvetex® products are based on a highly porous, polystyrene scaffold structure with a uniform and welldefined architecture that provides an excellent environment for cells to acquire and maintain their natural three-dimensional shape and organization during incubation.
The Alvetex®Scaffold technology therefore gives more biologically relevant data by overcoming the limitations of traditional monolayer cultures.
In combination with the flexibility and reliability of the Freedom EVO platform, it will provide powerful solutions for automated growth and maintenance of 3D cell cultures, allowing researchers to develop more reliable and powerful cellular assays.
Kevin Moore, Head of Applications and Solutions at Tecan, said: “We are delighted to be working with Reinnervate and look forward to combining our mutual expertise and technical abilities to develop ground-breaking solutions for cell biology customers.”
Richard Rowling, Commercial Director at Reinnervate added: “We are delighted that Tecan have decided to put Alvetex®Scaffold at the heart of their plans for the automation of 3D cell culture. We believe that this agreement is great news for cell biologists, as Alvetex®Scaffold is becoming the industry standard for scientists who need to retain the native structure and functionality of cells to better mimic in-vivo biological models.”
Using Milk Protein to 3D-Imprint Muscle and Bone CellsNews
Researchers from the University of Canterbury are replicating a 3D imprint of cells onto films made of milk protein. The films then gradually degrade, leaving the grown tissue behind.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018
EMBL Course: Brillouin Microscopy: Emerging Tool for Probing Mechanical Properties of Living Cells
Jan 17 - Jan 19, 2018